Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2017

Profiling Precursor Lipids for Specialized Pro-Resolution
Molecules in Platelet-Rich Fibrin Following Fish Oil and Aspirin
Intake
Danielle M. McCormack

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Periodontics and Periodontology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/4761

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

© Danielle M. McCormack
All Rights Reserved

2017

Profiling Precursor Lipids for Specialized Pro-Resolution Molecules in Platelet-Rich Fibrin
Following Fish Oil and Aspirin Intake

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Dentistry at Virginia Commonwealth University.

By
Danielle M. McCormack
BS Florida State University, Tallahassee 2009, DDS Virginia Commonwealth University 2014
,
Director: Parthasarathy A. Madurantakam
Assistant Professor, Department of General Practice
School of Dentistry

Virginia Commonwealth University
Richmond, Virginia
May 2017

ii
Acknowledgment

I would like to thank my committee, Dr. Parth Madurantakam, Dr. Dayanjan Wijesinghe, Dr.
Thomas Waldrop, and Dr. Al Best for their support and guidance with all aspects of this research
project. I would also like to thank Kim Hollaway for her excellence in phlebotomy training. I
would like to express my appreciation to both the VCU Graduate Periodontics department for
funding and Salvin for their generous donation of equipment.

iii
Table of Contents

List of Tables ................................................................................................................................. iv
List of Figures ................................................................................................................................. v
Abstract .......................................................................................................................................... vi
Introduction ..................................................................................................................................... 1
Materials and Methods .................................................................................................................... 8
Results ........................................................................................................................................... 14
Discussion ..................................................................................................................................... 16
Conclusions ................................................................................................................................... 20
References ..................................................................................................................................... 21
Tables ............................................................................................................................................ 25
Figures........................................................................................................................................... 32
Appendices .................................................................................................................................... 40
Vita................................................................................................................................................ 52

iv

List of Tables

Table 1. Differences between the four treatment groups .............................................................. 25
Table 2. Aspirin and EFA effects ................................................................................................. 26
Table 3. ANCOVA results, P-values for each Lipid .................................................................... 27

v

List of Figures
Figure 1: Chronology of events in acute inflammation and its resolution. ................................... 32
Figure 2: A Schematic showing the paradigm shift in the approach towards treating chronic
unresolved inflammation including periodontitis. ......................................................... 33
Figure 3: Transcellular biosynthesis of SPM during platelet-neutrophil interaction. ................... 34
Figure 4: Table of SPM mediators. ............................................................................................... 35
Figure 5: Essential fatty acid production and metabolism to form eicosanoid signaling molecules,
some of which are pro-inflammatory and others pro-resolving..................................... 36
Figure 6: A. Armamentarium for the PRF preparation with labeled tubes for sample collection. B
is the centrifuge used for PRF preparation (Intra-Lock, FL) ......................................... 37
Figure 7: Clinical steps involved in generating PRF. ................................................................... 38
Figure 8: Flow chart of study protocol. ........................................................................................ 39

vi
Abstract

PROFILING PRECURSOR LIPIDS FOR SPECIALIZED PRO-RESOLUTION MOLECULES
IN PLATELET-RICH FIBRIN FOLLOWING FISH OIL AND ASPIRIN INTAKE
by
Danielle M. McCormack, MSD
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Dentistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2017

Major Director: Parthasarathy A. Madurantakam
Assistant Professor, Department of General Practice,
VCU School of Dentistry

Background: Current research has demonstrated that aspirin and fish oil (EFA) increase plasma
levels of specialized pro-resolution molecules (SPMs). This study investigates their effects on
SPM precursor pools in platelet rich fibrin (PRF). Methods: Twenty healthy volunteers were
randomly assigned to take aspirin; EFA or aspirin and EFA. Four hours later, SPM precursor
levels were quantified using combined Liquid Chromatography tandem mass spectrometry. The
differences between the groups: Aspirin (yes or no), EFA (yes or no), were analyzed by
ANCOVA, testing for group differences after covarying out the baseline value. Results: There
were 4 significant interactions, 1 with an aspirin effect, 2 with an EFA effect, and 64 with no

vii
difference between the groups. The significant interaction effect was found for the following
lipidome: LPE(20:4), LPI(16:1), LPI(18:1), and LPI(20:3). Aspirin decreased the LPG(16:4)
levels, and EFA decreased the LPE(22:5) and PG(16:0/18:0) lipidomes. Conclusions: Some
SPM precursor pools in PRF were increased following supplementation.

Keywords: Platelet-rich fibrin, specialized pro-resolution molecules, mass spectrometry,
precursor lipids, EFA, aspirin.

Introduction

Periodontal Disease is a chronic inflammatory disease: It is becoming increasingly clear that
bacteria are necessary, but not always sufficient to produce disease (1) and the tissue destruction
is a result of exaggerated host inflammatory response to the biofilm. In addition to being
associated with a variety of systemic diseases, (2) chronic periodontitis is the most prevalent
disease affecting almost half of the US adult population (3).
Acute Inflammation and Its Resolution
In response to injury or infection, the protective program of acute inflammation and its complete
and timely resolution are critical for the restoration of tissue homeostasis. This highly
coordinated and synergistic program combines the distinct actions of multiple cell types to
achieve pathogen eradication and subsequent tissue repair. The acute inflammatory response can
be divided into 2 general phases: initiation and resolution (4, 5).
Initiation is marked by:
a.

Tissue edema resulting from increased blood flow and permeability of the

microvasculature; processes that are mediated, in part, by lipid mediators (ie, leukotrienes
and prostaglandins) and other vasoactive products (ie, histamine and bradykinin).
b.

Subsequently, polymorphonuclear neutrophils (PMN) migrate to the area to

defend against microbial invasion. Drawn to the site of injury by chemical signals
including proinflammatory lipid mediators, PMN traverse the vasculature through precise
interactions with endothelial adhesion receptors and subsequently engulf and degrade
pathogens within phagolysosomes.
The resolution phase is already being enacted at this early point as:
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a. The influx of PMN is halted at a level appropriate for the insult and is accompanied by
their timely apoptosis.
b. Monocytes subsequently infiltrate the tissue where they differentiate into macrophages
that avidly respond to the so-called find-me and eat-me signals (ie, nucleotides and
externalized phosphatidylserine) released or presented by apoptotic cells such as PMN.
c. Uptake of apoptotic cells by macrophages (ie, efferocytosis) is an anti-inflammatory
process associated with decreased production of inflammatory mediators, thus coupling
the initiation of inflammation with its ultimate resolution.
d. The timely clearance of microbes and apoptotic cells is required to prevent bystander
tissue damage and to set the stage for tissue repair and regeneration, allowing for the
return to homeostasis.
e. Active clearance of apoptotic cells is a key defining feature of resolution, as failed
clearance can lead to cellular necrosis and exacerbated inflammation beyond the initial
insult, impeding tissue repair.
Critical to progressing from initiation to resolution is the temporal switch in lipid
mediators that are biosynthesized by leukocytes in the tissue, a process known as lipid mediator
class switching (Figure 1). Interruption of this process at any point (ie, prolonged leukocyte
recruitment and survival, impairments in apoptotic cell removal, and alterations in macrophage
phenotype switching) could potentially lead to chronic inflammation with resultant tissue
damage, excessive fibrosis, and loss of function (5, 6).
Resolution of inflammation is an active, agonist-mediated, well-orchestrated return of
tissue homeostasis. It is important to realize that anti-inflammation and resolution are completely
independent mechanisms that affect the final outcome. While anti-inflammation is a

2

pharmacologic intervention, resolution is biologic pathways that restore tissue homeostasis. A
growing body of research suggests that chronic inflammatory periodontal disease is at least
involves a failure of resolution pathways to restore homeostasis.
For several years, anti-inflammatory agents were used for prevention and management of
inflammatory diseases. However anti-inflammation is not the same as resolution. Once the
inflammatory response is initiated, a continuous cascade of events takes place during which the
body attempts to eliminate invaders through proinflammatory actions of cells and their products.
The symptoms of inflammation are relieved primarily due to catabolism of proinflammatory
mediators.
Recently, the possibility of using potent ‘resolution agonists’ to orchestrate the return of
the tissue to homeostasis and rescue resolution deficits has been proposed and is promising
(Figure 2). Existing data demonstrate that natural pathways of resolution can be used to limit
inflammation and promote healing and regeneration with a minimal risk of side effects. Within
this context, lipid mediators represent a paradigm change in the management of periodontal
diseases (7).
Platelets and Acute Inflammation:
Platelets or thrombocytes are one of the important components of blood that play very important
role in hemostasis, inflammation and regeneration. Normal platelet counts in whole blood are in
the range of 150,000 to 400,000 per micro-liter. Autologous platelet concentrates (APC) are
derived from patients' own blood and are processed to enrich the amount of platelets to at least
1,000,000 per micro-liter. Such a high concentration of platelets is expected to be a potent source
of endogenous peptide growth factors and cytokines like PDGF, IGF, VEGF and FGF that
stimulate healing of bone and soft tissues (8).
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In contrast to anti-inflammatory effects of growth factors, its resolution is orchestrated by
a family of lipid molecules called specialized pro-resolving mediators (SPM) including lipoxins,
resolvins, maresins and protectins (9),(10).
Specialized Pro-resolving Mediators- Lipoxins and Resolvins:
Lipoxins (LX): are trihydroxy-products derived from arachidonic acid (AA) through the
cooperative interaction of diverse cell types in the inflammatory milieu- neutrophils, eosinophils,
monocytes, platelets, and endothelial cells. The dense clustering of different cell types presents a
unique situation for lipid handling. In contrast to the synthesis of protein mediators (ie,
cytokines), lipid mediators can be produced along enzyme pathways that involve multiple cells,
in a process known as transcellular biosynthesis (Figure 3). Under the action of cytosolic
phospholipase A, membrane AA is immediately secreted into the extracellular milieu, where it is
taken up and used by nearby cells. In this way, the inflamed tissue becomes a specialized organ
for lipid metabolism, producing the types and amounts of lipid mediators needed to promote or
resolve inflammation.
There are two major routes of LX production from AA in humans. The type of
lipoxygenase that initiates AA oxygenation can distinguish these, and these are distributed
differently by cell type. The first pathway involves the insertion of molecular oxygen at C-5 by
5-lipoxygenase (5-LO) in concert with the 5-LO activating protein (FLAP) to produce 5hydroperoxyeicosatetraenoic acid (5-HpETE), which is further metabolized by 5-LO to produce
the intermediate, leukotriene A (LTA). This pathway is conducted solely by leukocytes, since the
distribution of 5-LO is largely restricted to these cell types. LTA4 is readily transferred to
adjacent cells, usually leading to its processing to other LTs (11). However, adherent platelets,
via 12-LO, will convert LTA4, donated by leukocytes, to LXA4 and LXB4. The second major
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route of LX biosynthesis involves the initial conversion of AA to 15(S)-HpETE by 15-LO.
Following secretion, 15(S)-HpETE is taken up by either neutrophils or monocytes and rapidly
converted through a 5-LO/ FLAP dependent mechanism to LXA4 and LXB4.
Resolvins (Rv) are endogenous chemical mediators that are biosynthesized from the major ω-3
fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), denoted E series
(RvE) and D series (RvD) resolvins, respectively. Like LX, Rv can be produced through
transcellular cooperation, initiated by enzymes in epithelial cells and completed by adjacent
leukocytes. Conceptually, the substrates EPA and DHA are released from membrane
phospholipids, metabolized in a transcellular fashion, and secreted in amounts sufficient to
reverse the course of inflammation. Ideally, this must happen throughout the inflamed tissue, at a
time that appropriately follows the elimination of the insult, which caused the inflammation,
continuing on to a return to homeostasis.
ω-3 fatty acids, Aspirin and SPM: Epidemiological, clinical, and animal studies provide
substantial support that the long chain ω-3 fatty acids from fish and fish oils, eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) improve outcomes associated with inflammation
(Figure 4) (12). The mechanisms by which ω-3 fatty acids exert their protection are still
emerging but likely include alterations in cell membrane composition and effects on gene
expression and receptors regulating signaling. The anti-inflammatory actions of ω-3 fatty acids
are, in part, related to reduce leukocyte-derived cytokine formation and modulation of eicosanoid
synthesis (13) (Figure 5). As mentioned above, resolution of inflammation is accomplished by
SPMs derived from EPA and DHA, known as E-series and D-series resolvins, respectively.
Aspirin irreversibly acetylates cyclooxygenase-2 (COX-2), inhibiting its ability to produce
prostanoids. However, acetylated COX-2 can metabolize AA to 15(R)-HETE, which may then
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be processed to the “aspirin-triggered” LX by 5-LO. Thus, epimers of LXA4 and LXB4 can be
produced following aspirin treatment. Similar to LX, aspirin-triggered Rv epimers are produced
by the acetylated COX-2/5-LO pathway.
Clinical studies involving supplementation of omega-3 fatty acids and detection of SPM
from human plasma samples using targeted liquid chromatography tandem mass spectrometry
(LC-MS/MS) have showed that the plasma levels of SPMs can be accurately quantified using
this technology and that these levels were increased within 4 hours of omega-3 and aspirin intake
(9). In another recent study, healthy volunteers were given ω-3 fatty acid supplements for seven
days and then randomized to receive aspirin or placebo in addition to ω-3 fatty acids during the
last two days. The study showed that ω-3 fatty acid supplementation for five days increased
plasma levels of 18-HEPE, 17-HDHA, 14-HDHA, and RvE1. Aspirin taken in addition to ω-3
fatty acids did not differentially affect any SPM. However, aspirin significantly reduced the ratio
of R- to S-isomers of 17-HDHA (14).
In a trial on 74 patients with chronic renal disease randomized to ω-3 fatty acids or
coenzyme Q10 (CoQ) for eight weeks, it was found that ω-3 Fatty acids significantly increased
plasma levels of 18-HEPE, 17-HDHA, and RvD1 while CoQ had no effect on any plasma SPM.
Regression analysis showed the increase in 18-HEPE and 17-HDHA following ω-3 fatty acids
was associated with a change in platelet EPA and DHA, respectively (15).
Patients with metabolic syndrome who started with reduced plasma concentrations of the
precursors of the E- and D- series resolvins had their plasma E-series resolvins increased
following ω -3 fatty acid supplementation and the addition of aspirin did not alter any of the
plasma SPMs in diseased and control subjects (16).
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Autologous Platelet Concentrates: Platelets or thrombocytes are one of the important
components of blood that play very important role in hemostasis, inflammation and regeneration.
Normal platelet counts in whole blood are in the range of 150,000 to 400,000 per micro-liter.
The efficacy of platelets is due to degranulation of alpha and dense granules where a variety of
growth factors responsible for regeneration is stored (17). Autologous platelet concentrates
(APC) are derived from patients' own blood and are processed to enrich the amount of platelets
to at least 1,000,000 per micro-liter.
One form of autologous platelet concentrate is platelet-rich fibrin (PRF), which is a
second-generation platelet concentrate that was developed in France by Choukroun that is being
used routinely in clinical practice (18, 19). The processing technique of PRF requires minimum
amount of blood to be harvested (10 ml) and has some advantages compared to platelet-rich
plasma (PRP) such as the simplified technique for preparation/application, minimal expense, and
lack of biochemical modification (no anticoagulant or bovine thrombin is required).
Considering the fact that platelet-rich fibrin (PRF) once applied is allowed to stay in contact with
the wound surface and stimulate a slow release of growth factors for 7 days and up to 28 days in
vitro (20, 21), it is important to know if the PRF has sufficient capacity to provide a continuous
supply of precursors for the continuous production of SPMs. In this study, we seek to investigate
the levels of precursors of SPM in PRF and the effect of administering essential fatty acid or
aspirin on the total levels of the precursors of these signaling lipids.
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Materials and Methods
Protocol:
The clinical study was undertaken after prior approved by the Institutional Review Board of
Virginia Commonwealth University (Study ID: HM20002473). Informed consent was obtained
from each participant. All experiments listed in this protocol involve handling of human blood
and/or blood products and appropriate personal protective equipment need to be worn at all
times. The waste were considered as biohazard and disposed of according to regulations. The
protocol for the entire procedure is listed in the Appendix 1.
Study Design:
Sixty study participants were recruited who satisfy the following inclusion/exclusion criteria.
Inclusion Criteria:
1. Healthy adults (>18 years of age)
2. Non-pregnant
3. Weight > 110 pounds
Exclusion Criteria:
1. History of smoking in the past 2 years
2. Individuals with known medical conditions and currently receiving treatment for the
same
3. History of anti-coagulant, immunosuppressive or antibiotic therapy in the last 6 months
4. History of non-steroidal anti-inflammatory drug use (Advil, Tylenol) in the past 2 days
or Aspirin in the past 10 days
5. History of essential fatty acid (fish oil supplement) intake in the past month
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6. Known allergic to fish oil components or nuts
Once written informed consent was obtained from the participant, the subject opened a sealed
envelope to determine the group he/she will fall into. The research coordinator assigned the
subjects into any one of the four groups with 15 participants each:
Group A: Control
Group B: Subjects taking one softgel of fish oil supplement (1400 mg, Sundown Naturals, NY)
Group C: Subjects taking one tablet of Bayer low-dose (81 mg) aspirin
Group D: Subjects with both EFA supplement (1.4 g) and aspirin (81 mg) 2 hours apart
Blood draw protocol:
Each patient had a total of 2 blood draws and the initial draw was done to establish the baseline.
After 4 hours after drug administration, the second blood draw was done. Personnel adequately
trained in phlebotomy performed the blood draws. At each time, 10 ml of blood was collected in
red top tubes and centrifuged in IntraSpin System (Intra-lock, FL) (Figure 6). The tubes were
centrifuged at 2700 rpm for 12 minutes at room temperature. The PRF membrane was separated
from the clot and was compressed using the Xpression Box for 30 sec (Figure 7). The PRF plugs
were transferred to labeled tubes with participant’s ID number, age, and sex, to protect
confidentiality. The labeled specimens were immediately stored at -80oC freezer to prevent
degradation until ready for analysis. When all samples were collected, the samples were thawed
and analyzed using the protocol described below.
Sample preparation for lipid extraction:
Lipids were extracted from the biological material using a modified Bligh and Dyer method (22).
Briefly, to 200μl of PRP 1ml of methanol containing the required internal standards were added
followed by the addition of 0.5 ml of chloroform. The monophasic mixture thus obtained was
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incubated at 4oC overnight. Depending on the analysis carried out, the extracted lipids were
either further purified using solid phase extraction or used as is following dilution to achieve the
target concentration in the linear dynamic range.
Lipid Quantification using LC-MS/MS:
These specialized pro-resolving mediators were analyzed using targeted LC MS/MS methods
using Shimadzu Nexera UPLC and a hybrid triple quadrupole linear ion trap (AB SCIEX 6500),
or via untargeted analysis using either LC MS/MS or shotgun lipidomics (AB SCIEX 5600). The
available lipid panel allowed quantification of following lipids:
FFA(16:1)

FFA(16:2)

FFA(24:1)

FFA(18:1)

FFA(18:2)

FFA(18:3)

FFA(20:0)

FFA(20:1)

FFA(20:3)

FFA(20:4)

FFA(20:5)

FFA(22:4)

FFA(22:5)

FFA(22:6)

FFA(24:0)

LPC(14:0) +AcO

LPC(16:1) +AcO

LPC(16:0) +AcO

LPC(18:0) +AcO

LPC(18:1) +AcO

LPC(18:2) +AcO

LPC(18:3) +AcO

LPC(20:0) +AcO

LPC(20:1) +AcO

LPC(20:2) +AcO

LPC(20:3) +AcO

LPC(20:4) +AcO

LPC(20:5) +AcO

LPC(22:4) +AcO

LPC(22:5) +AcO

LPC(22:6) +AcO

LPE(16:0)

LPE(16:1)

LPE(18:0)

LPE(18:1)

LPE(18:2)

LPE(18:3)

LPE(20:0)

LPE(20:1)

LPE(20:2)

LPE(20:3)

LPE(20:4)
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LPE(20:5)

LPE(22:4)

LPE(22:5)

LPE(22:6)

LPG(14:0)

LPG(18:1)

LPG(18:3)

LPG(20:1)

LPG(20:3)

LPG(20:4)

LPG(22:4)

LPG(22:5)

LPG(22:6)

LPI(16:0)

LPI(18:0)

LPI(18:1)

LPI(18:2)

LPI(20:3)

LPI(20:4)

LPS(18:0)

PE(18:2/20:1)

PE(P-16:0/16:0)

PS(18:2/22:6)

SM(14:0)

SM(16:0)

SM(18:0)

SM(18:1)

SM(20:0)

SM(20:1)

SM(22:0)

SM(22:1)

SM(24:0)

SM(24:1)

SM(26:0)

SM(26:1)

where:
SM=Sphingomyelin
LPC=Lysophosphotidylcholine
LPE=Lysophosphatidylethanolamine
LPG=Lysophosphatidylglycerol
LPI=Lysophosphotidylinositol
LPS-Lysopphosphatidylserine
PS=Phosphatidylserine
FFA=Free Fatty Acids
PE= Phosphatidylethanolamine
11

The number designation is for the following (XX:Y):
XX=number of carbon atoms in the acyl chain. Also referred to as the chain length.
Y=number of double bonds in the acyl chain.

Statistical analysis:
Participants were randomly assigned to one of four group intervention groups using a two-bytwo design (ETA=No or Yes and Aspirin=No or Yes) and there was a specimen collection at
baseline and post-intervention. The statistical method used to analyze this question was an
analysis of covariance (ANCOVA) with the following effects: Baseline covariate, Aspirin, EFA,
and the EFA*Aspirin interaction. There are thus three questions of interest.


The p-value associated with the Aspirin effect answers this question: Is the postintervention mean of the Aspirin=No groups different than the post-intervention mean of
the Aspirin=Yes groups, after covarying out the patients’ baseline? Question: Does
Aspirin have a simple effect?



The p-value associated with the EFA effect answers this question: Is the post-intervention
mean of the EFA=No groups different than the post-intervention mean of the EFA=Yes
groups, after covarying out the patients’ baseline? Question: Does EFA have a simple
effect?



The p-value associated with the EFA*Aspirin interaction answers this question: Does the
effect of EFA differ in the Aspirin=No and Aspirin=Yes groups, after covarying out the
patients’ baseline. Question: Is the effect of EFA and Aspirin complicated?

In statistical analysis, the answer to the interaction question is inspected first. And so, the results
will be reported according to the following patterns:
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4 Treatments: In those lipid precursors where there is a significant EFA*Aspirin
interaction, all possible treatment group differences will be inspected by Tukey’s HSD
multiple-comparison procedure and the differences summarized.



Aspirin: In those lipid precursors where there is no significant interaction, but there is a
significant Aspirin effect, the two Aspirin groups will be compared.



EFA: In those lipid precursors where there is no significant interaction, but there is a
significant EFA effect, the two EFA groups will be compared.



No effect: In those lipid precursors with no significant interaction effects and no
significant main effects, the lipid precursors will be listed.
All analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary

NC). Statistical significance was declared at alpha = 0.05. (Unfortunately, in this small study) No
correction for multiple comparisons was applied.
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Results
Flow of Participants
For this study, 20 of the participant samples were available for analysis. There were 5
participants in group A, 6 in group B, 4 in group C, and 5 in group D (Figure 8).
Significant interactions
There were 71 SPM screened in the 20 PRF subjects. There were 4 SPMs with a significant
interaction, 1 with an Aspirin effect, 2 with an EFA effect, and 64 with no apparent difference
between the groups.
Interaction effect
There was a significant interaction effect for these SPMs: LPE(20:4), LPI(16:1), LPI(18:1), and
LPI(20:3). These results are shown in Table 1 where the means for the four treatment groups are
ordered by size in the right-hand column. Means sharing the same superscript were not
significantly different.
The pattern that is evident for LPE(20:4) is that there is no significant EFA difference
(P=0.061), no significant Aspirin difference (P=0.458) but a significant interaction (P=0.046).
That is, there is some evidence for a difference between the four groups but the pattern is not
simple. As may be seen by the fact that all four means share the same “a” superscript, the
multiple comparison procedure cannot identify which of the groups were different.
The pattern for LPI(16:1) is clearer. The EFA=No Aspirin=No group has a significantly
higher mean LPI(16.:1) than any of the other three groups.
The pattern for LPI(18:1) and LPI(20:3) is that the EFA=No Aspirin=NO group is only
significantly higher than the EFA=No Aspirin=Yes group. And the other two groups were not
different from any of the other groups.
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Aspirin effect
The only significant Aspirin effect was evident in LPG(16:1).
EFA effect
A significant EFA effect was evident in LPE(22:5) and PG(16:0/18:0). The Aspirin and EFA
effects are shown in Table 2. For LPG(16:1) the no Aspirin group had higher levels than the
Aspirin groups (a difference of -0.04, P=0.044). For LPE(22:5) the no EFA group had lower
mean than the EFA group (a difference of 16.3, P=0.050). For PG(16:0/18:0) the no EFA groups
had higher mean than the EFA group (a difference of -3.6, P=0.016).
No effect evident
There was no difference between the groups for these metabolomics: FFA(16:1), FFA(16:2),
FFA(18:1), FFA(18:2), FFA(18:3), FFA(20:0), FFA(20:1), FFA(20:3), FFA(20:4), FFA(20:5),
FFA(22:4), FFA(22:5), FFA(22:6), FFA(24:0), FFA(24:1), LPC(14:0) +AcO, LPC(16:0) +AcO,
LPC(16:1) +AcO, LPC(18:0) +AcO, LPC(18:1) +AcO, LPC(18:2) +AcO, LPC(18:3) +AcO,
LPC(20:0) +AcO, LPC(20:1) +AcO, LPC(20:2) +AcO, LPC(20:3) +AcO, LPC(20:4) +AcO,
LPC(20:5) +AcO, LPC(22:4) +AcO, LPC(22:5) +AcO, LPC(22:6) +AcO, LPE(14:0),
LPE(16:0), LPE(16:1), LPE(18:0), LPE(18:1), LPE(18:2), LPE(18:3), LPE(20:0), LPE(20:1),
LPE(20:2), LPE(20:3), LPE(20:5), LPE(22:4), LPG(20:1), LPG(20:3), LPG(20:5), LPG(22:5),
LPI(16:0), LPI(18:0), LPI(18:2), LPI(20:4), SM(14:0), SM(16:0), SM(18:0), SM(18:1),
SM(20:0), SM(20:1), SM(22:0), SM(22:1), SM(24:0), SM(24:1), SM(26:0), and SM(26:1).
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Discussion
Acute inflammation is the body’s natural response to tissue injury and the failure to resolve
inflammatory processes can lead to persistent low-grade inflammation. This chronic
inflammation is associated with many diseases including periodontal disease, diabetes,
rheumatoid arthritis, and inflammatory bowel disease (23). During periodontal surgery, soft
tissue and bone augmentation procedures create acute tissue trauma and in turn trigger an
inflammatory response. Immediate management of the wound site at time of surgery can
improve both the healing process and patient’s postoperative pain. To help manage the acute
inflammation that occurs after surgery, better knowledge of the active process of resolution of
inflammation and healing are needed.
There are many different cell types and signaling pathways involved in wound healing
and it has been established over the past few decades that lipid signaling pathways play a
dominant role (24). Serhan has shown that resolution of inflammation is not a passive process
but an active one that is mediated by specialized pro-resolution molecules (SPMs) (25). SPM
activity has been linked to cessation of polymorphonuclear leukocyte (PMN) recruitment to the
wound site, and enhancement of macrophage uptake of debris, bacteria, and apoptotic cells to aid
in inflammatory resolution and return to homeostasis. It has also been demonstrated that SPMs
are increased in blood plasma and platelet concentrates with the intake of aspirin and essential
fatty acids (EFA). This is due to increasing omega-3 fatty acids EPA and DHA triggering the
“classical” pathway for SPM production as well as the “aspirin-trigger” pathway biosynthesis of
specific epimers of these mediators. What is less understood are the lipid precursors along these
pathways and whether manipulation of these precursors would provide a longer acting beneficial
effect on wound healing.
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Autologous platelet concentrates (APC) are currently being employed in the field of
regenerative medicine because of the abundance of peptide growth factors and cytokines.
Platelet-rich fibrin (PRF) brought about a huge advance in the evolution of platelet concentrates.
Whereas platelet-rich plasma (PRP) undergoes rapid activation with the use of thrombin that can
cause fibrinogen polymerization to be incomplete and result in friable fibrin gels, PRF forms a
dense fibrin membrane with entrapped platelets that allows the slow release of growth factors
over a longer period of time (19, 20, 26). The preparation of L-PRF allows for the processes of
fibrinogen polymerization, platelet enhancement, and activation to occur simultaneously in one
tube without the use of anticoagulant, bovine thrombin, or calcium chloride. This method of
concentrating platelets not only simplifies the process when compared to PRP, but also
significantly decreases costs. One important consideration in generating consistent L-PRF
membranes is the speed of blood collection and immediate centrifugation of tubes, typically
within a minute. If either harvesting of blood or transfer to centrifuge is prolonged, then the
result is formation of a small incoherent, friable mass of fibrin with unknown content. Once the
PRF clot is formed, it can be compressed into membranes and/or plugs to be utilized for surgical
application.
Although aspirin and fish oil have been shown to increase the levels of SPMs when
examined in both whole blood and platelet concentrates, the levels of their lipid precursor
molecules have never been investigated before now. Considering that PRF is able to stimulate a
slow release of growth factors, it is important to know if the PRF has sufficient capacity to
provide a continuous supply of precursors for the continuous production of SPMs and if
administering essential fatty acid or aspirin has an effect on the total levels of the precursors of
these bioactive lipids.
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In this pilot study, lipids were measured in multiple forms that can be precursors to
SPMs. Whereas free fatty acids may be used as immediate precursors, lysophospholipids are
stored precursors that need an enzyme to be activated prior to potential SPM conversion. This
stored form of lipid precursors has the potential to be cleaved and increase the available free fatty
acids to be used as an immediate source for potential conversion to SPMs. The data presented in
this experiment includes a population of 20 healthy adult participants. Seventy-one lipid
precursor molecules were quantified by analyzing platelet-rich fibrin plugs, by means of liquid
chromatography mass spectrometry. We found four lipid precursors with significant interactions
when both aspirin and EFA were administered, one with an Aspirin effect, and two with a
significant EFA effect.
A significant interaction effect for LPE(20:4), LPI(16:1), LPI(18:1), and LPI(20:3) are
shown in Table 1. LPE(20:4) is derived from a phosphatidylethanolamine, which is typical of
cell membranes. This lipid precursor was seen to have a significant interaction when taking both
aspirin and fish oil (P=0.046) but only a pattern towards significance when comparing mean
values. The physiological significance of human plasma LPE remains unknown (15). The higher
average of molecule LPI (16:1), LPI(18:1), and LPI(20:3) in the control groups compared to the
groups receiving an intervention, indicates an overall increase in their metabolism with
treatment. Both LPE and LPI are lysophospholipids derived from phospholipids, which are
bioactive lipid molecules that make act as signaling mediators. In order to understand what
signaling effects these lysophospholipids are contributing to, it would be necessary to know what
free fatty acid chain was cleaved to contribute to either proinflammatory or anti-inflammatory
pathways and would need further analysis.
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The only significant Aspirin effect was evident in LPG(16:1), in which LPG is a
precursor for synthesis of phosphatidylglycerol (PG). A significant EFA effect was evident in
LPE(22:5) and PG(16:0/18:0). The increase in LPE(22:5) is noteworthy and has never been
reported before and may indicate an increased metabolism of arachidonic acid to a longer chain
omega-6 docosapentaenoic acid that does not give rise to inflammatory lipids. It can also
indicate a buildup of precursor lipid omega-3 docosapentaenoic acid, for conversion to DHA,
which is a precursor for SPM. Either way, this leads to a decrease in inflammation. Additional
studies using flux analysis are needed to understand the exact mechanism.
The most notable limitations of this study are the sample size taken to perform the pilot
study and not having the ability to analyze all samples taken. This was due to having limited
available access to liquid chromatography tandem mass spectrometry equipment. Lipid
precursors may have also been available in the supernatant that was compressed from the PRF
plug and was not included in this pilot study analysis. Another limitation may be due to only
giving a single dose of aspirin or fish oil. It is possible that more lipid precursors did not have a
significant change due to the dose and time examined. It may be anticipated that a higher dose
administered over a longer timeframe would show a change in these precursor pools.
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Conclusions

In this pilot study, findings indicate that the pattern for LPI(16:1) for EFA=No, Aspirin=No
group has a significantly higher mean LPI(16:1) than any of the other three groups. This
indicates a higher average of molecule LPI (16:1) in the control group compared to the groups
receiving an intervention, indicating a metabolism of this molecule during treatment.
The pattern for LPI(18:1) and LPI(20:3) is that the EFA=No, Aspirin=No group is only
significantly higher than the EFA=No, Aspirin=Yes group. This also demonstrates higher levels
LPI(18:1) and LPI(20:3) in the control group than compared to the aspirin group and again
indicates an overall increase in their metabolism with treatment. The decrease in LPI with these
treatments have never been reported before and is worth investigating further due to their
signaling potential.
The increase in LPE(22:5) is noteworthy and has never been reported before. It may
indicate an increased metabolism of arachidonic acid to a longer chain omega-6 docosapentaenoic
acid that does not give rise to inflammatory lipids. It can also indicate a build up of precursor lipid
omega-3 docosapentaenoic acid, for conversion to DHA, which is a precursor for SPM. Either
way, this leads to a decrease in inflammation. Additional studies using flux analysis are needed to
understand the exact mechanism.
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Tables
Table 1. Differences between the four treatment groups

Lipid

Effects

EFA Aspirin

Mean

Yes

Yes

436.36 a

No

No

240.44 a

EFA*Aspirin P=0.046 Yes

No

226.08 a

No

Yes

138.57 a

No

No

0.59 a

Yes

No

0.26 b

EFA*Aspirin P=0.014 Yes

Yes

0.22 b

No

Yes

0.18 b

No

No

9.74 a

Yes

No

7.16 ba

EFA*Aspirin P=0.026 Yes

Yes

6.94 ba

No

Yes

4.78 b

No

No

1.94 a

Yes

Yes

1.63 ba

EFA*Aspirin P=0.010 Yes

No

1.49 ba

No

Yes

0.73 b

LPE(20:4) EFA P=0.061
Aspirin P=0.458

LPI(16:1) EFA P=0.038
Aspirin P=0.006

LPI(18:1) EFA P=0.833
Aspirin P=0.016

LPI(20:3) EFA P=0.349
Aspirin P=0.037
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Table 2. Aspirin and EFA effects

Lipid

Difference

Means
Aspirin effects

LPG(16:1)

-0.041 (-0.081 to -0.001) 0.134 no Aspirin
P=0.044

0.093 Aspirin
0.105 Baseline
EFA effects

LPE(22:5)

16.390 (0.006 to 32.775) 19.852 no EFA
P=0.050

36.242 EFA
22.976 Baseline

PG(16:0/18:0) -3.633 (-6.493 to -0.774) 6.212 no EFA
P=0.016

2.579 EFA
3.738 Baseline
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Table 3. ANCOVA results, P-values for each Lipid

Lipid

Aspirin

EFA

EFA*

Pre

Aspirin
FFA(16:1)

0.1134 0.2765

0.8483 0.7883

FFA(16:2)

0.2280 0.2148

0.8151 0.0313

FFA(18:1)

0.7327 0.6863

0.0779 0.1488

FFA(18:2)

0.2949 0.0604

0.3193 0.0005

FFA(18:3)

0.9411 0.7432

0.8723 0.7994

FFA(20:0)

0.0558 0.2681

0.3967 0.0697

FFA(20:1)

0.3146 0.7453

0.2332 0.0006

FFA(20:3)

0.5031 0.3891

0.1483 0.0063

FFA(20:4)

0.6229 0.9564

0.7267 0.5921

FFA(20:5)

0.7321 0.7588

0.5490 0.2683

FFA(22:4)

0.4904 0.9009

0.4384 0.1746

FFA(22:5)

0.2601 0.6193

0.0623 0.0901

FFA(22:6)

0.4266 0.7917

0.3351 0.4565

FFA(24:0)

0.4990 0.4600

0.2452 0.1853

FFA(24:1)

0.3082 0.6190

0.4226 0.0188

LPC(14:0) +AcO

0.7961 0.6492

0.4487 0.5090
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Lipid

Aspirin

EFA

EFA*

Pre

Aspirin
LPC(16:0) +AcO

0.5781 0.5480

0.4745 0.9894

LPC(16:1) +AcO

0.4578 0.9997

0.2303 0.9529

LPC(18:0) +AcO

0.3074 0.5937

0.7867 0.3154

LPC(18:1) +AcO

0.9721 0.5483

0.1992 0.4134

LPC(18:2) +AcO

0.5063 0.9930

0.5849 0.6353

LPC(18:3) +AcO

0.6026 0.5640

0.2827 0.0296

LPC(20:0) +AcO

0.3275 0.3352

0.4722 0.2388

LPC(20:1) +AcO

0.8535 0.5375

0.3874 0.2317

LPC(20:2) +AcO

0.8742 0.5972

0.3778 0.4174

LPC(20:3) +AcO

0.4859 0.5306

0.2163 0.0850

LPC(20:4) +AcO

0.9823 0.9258

0.5881 0.4450

LPC(20:5) +AcO

0.4735 0.3225

0.1444 0.0010

LPC(22:4) +AcO

0.7142 0.7474

0.7388 0.2624

LPC(22:5) +AcO

0.2108 0.6177

0.3307 0.1974

LPC(22:6) +AcO

0.4761 0.9833

0.3732 0.0506

LPE(14:0)

0.1793 0.3970

0.2428 0.0669

LPE(16:0)

0.7005 0.2076

0.0942 0.9935
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Lipid

Aspirin

EFA

EFA*

Pre

Aspirin
LPE(16:1)

0.2777 0.2778

0.3036 0.6181

LPE(18:0)

0.8110 0.3866

0.3843 0.6836

LPE(18:1)

0.3142 0.7656

0.1856 0.3545

LPE(18:2)

0.6997 0.4158

0.2101 0.2262

LPE(18:3)

0.9577 0.8959

0.7692 0.7763

LPE(20:0)

0.9550 0.3013

0.2697 0.4460

LPE(20:1)

0.5246 0.2362

0.1532 0.9159

LPE(20:2)

0.3787 0.0923

0.2240 0.1346

LPE(20:3)

0.8393 0.1124

0.1362 0.9534

LPE(20:4)

0.4584 0.0610

0.0464 0.1909

LPE(20:5)

0.3790 0.0750

0.2625 0.4191

LPE(22:4)

0.4239 0.1201

0.1075 0.2690

LPE(22:5)

0.3420 0.0499

0.1061 0.5516

LPG(16:1)

0.0438 0.4291

0.6619 0.5802

LPG(20:1)

0.8288 0.8144

0.4608 0.7720

LPG(20:3)

0.0733 0.7316

0.1516 0.0023

LPG(20:5)

0.1938 0.0972

0.4038 0.0521
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Lipid

Aspirin

EFA

EFA*

Pre

Aspirin
LPG(22:5)

0.9600 0.3974

0.9015 0.8531

LPI(16:0)

0.4146 0.1875

0.1078 0.6380

LPI(16:1)

0.0058 0.0380

0.0139 0.4214

LPI(18:0)

0.2808 0.2564

0.7044 0.9164

LPI(18:1)

0.0158 0.8329

0.0261 0.9410

LPI(18:2)

0.2211 0.2269

0.1281 0.0385

LPI(20:3)

0.0365 0.3494

0.0105 0.1140

LPI(20:4)

0.0801 0.5070

0.1423 0.0959

PG(16:0/18:0)

0.3901 0.0164

0.5864 0.2215

SM(14:0)

0.5624 0.6177

0.4243 0.1714

SM(16:0)

0.4958 0.4171

0.4737 0.9161

SM(18:0)

0.7107 0.5754

0.3900 0.3132

SM(18:1)

0.7436 0.4500

0.4113 0.1881

SM(20:0)

0.8712 0.5778

0.4134 0.3613

SM(20:1)

0.9408 0.5706

0.4484 0.0758

SM(22:0)

0.6240 0.3385

0.6077 0.7652

SM(22:1)

0.8315 0.5123

0.5410 0.3200
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Lipid

Aspirin

EFA

EFA*

Pre

Aspirin
SM(24:0)

0.4012 0.3135

0.5452 0.6122

SM(24:1)

0.6555 0.3851

0.2425 0.8221

SM(26:0)

0.4039 0.3545

0.4777 0.4562

SM(26:1)

0.5139 0.3585

0.2838 0.6842
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Figures

Figure 1: Chronology of events in acute inflammation and its resolution.
Source: Adapted from Circulation Research. 2016;119:113-130
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Figure 2: A Schematic showing the paradigm shift in the approach towards treating
chronic unresolved inflammation including periodontitis.
Source: http://www.eumbrella.org/timer_objectives.html
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Figure 3: Transcellular biosynthesis of SPM during platelet-neutrophil interaction.
Source: Levy G, Serhan C. Resolution and regulation of inflammation. Pathobiology of human
disease. 2014;332-348
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Figure 4: Table of SPM mediators.
Source: Serhan C. Novel lipid mediators and resolution mechanisms in acute inflammation: To
resolve or not? Am J Pathol. 2010 Oct;177(4):1576-1591
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Figure 5: Essential fatty acid production and metabolism to form eicosanoid signaling
molecules, some of which are pro-inflammatory and others pro-resolving.
Source: https://en.wikipedia.org/wiki/Eicosanoid

36

Figure 6: A. Armamentarium for the PRF preparation with labeled tubes for sample
collection. B is the centrifuge used for PRF preparation (Intra-Lock, FL)
Source: http://www.dentalimplants.clinic/services/surgical-procedures
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Figure 7: Clinical steps involved in generating PRF.
A: Blood draw; B: Different layers of PRF in a tube; C: Preparing the membrane to form a
plug; D: Compressed plug ready for storage.
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Figure 8: Flow chart of study protocol.
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Appendices
Appendix 1: Chair-side PRF Research Protocol
Before blood draw

1. Prepare the materials basket which should include: a phlebotomy kit, goggles, 6 prelabeled PRP tubes, 3 pre-labeled PRF tubes, 3 5 mL syringes, goggles, 1 stopcock, 1
blood needle, 3 1 mL syringes with needles, ascorbic acid, calcium chloride, thrombin,
and 5 glass vials with labels
2. Use a 5 mL syringe to draw 5 mL of calcium chloride and inject into the thrombin vial.
Mix and let it sit until ready to use
3. Load 0.5 mL of ascorbic into a 1 mL syringe
4. Load 0.5 mL of the calcium chloride and thrombin mixture into the 2 other 1 mL syringes
and leave for use after obtaining the blood samples
5. Meet with the subject and have them fill out the screening form
6. If the subject is eligible, review the participant consent form with the subject and if they
wish to participate in the study have he/she sign the consent form with you as witness
7. Write the subjects name onto the data sheet and let them know if they are in group A, B,
C or D
8. Inform the subject how to take their medication accordingly
9. Ask the subject if they are ready for the blood draw or if they would like to schedule for
another day
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During the blood draw
1. Bring out the phlebotomy kit which should include: 1 butterfly needle, 6 pre-labeled PRP
tubes, 3 pre-labeled PRF tubes, gauze, 1 band aid, 1 test tube rack, 1 tourniquet, and 1
alcohol swab.
2. Put on gloves and goggles and ask the patient which arm they prefer to get the blood
drawn from
3. Wrap the tourniquet tightly around their desired arm and locate the vein you wish to use.
4. Disinfect the area using the alcohol swab and allow 30 seconds for the area to dry.
5. Proceed to inject the butterfly needle and draw 8 mL of blood into each PRF tube.
6. Mix the contents of each tube by inverting the tube 5-8 times then place each tube on the
rack
7. Remove the tourniquet and place some gauze on the injected area, before removing the
butterfly needle
8. Apply pressure with the gauze until the bleeding has stopped or apply a band aid
9. Thank and discharge the patient, confirming that they will be returning in 4-6 hours
10. Clean/disinfect the patient area
After the blood draw
1. Place 1 of the PRF tubes labeled whole blood into the freezer for storage. Place the
remaining two PRF tubes in opposite sides of the PRF centrifuge.
2. Press the green button and centrifuge for 12 minutes
3. Remove the 2 PRF tubes from the PRF centrifuge
4. Place them onto a clean tray and bring out the Xpression kit which should include a tray,
weight, small dish, scalpel, and tweezers.
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5. Use tweezers to remove the PRF layer from each of the tubes and place them on the
Xpression tray. Make sure the PRF layers are directly above the small dish.
6. Use a scalpel to remove the red blood cells.
7. Place the weight on top of the PRF layers for 30 seconds.
8. Collect the PRF pellets and place them into separate labeled vials and then collect the
liquid that is now in the small dish and transfer it into a separate labeled vial.
9. Store all 3 samples into the freezer
10. Clean and disinfect the area.
11. Repeat the protocol when the patient arrives 4-6 hours later.
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Appendix 2: Study key for preparation of PRF before medication taken and 4 hours after
medication taken.
Color code for preparation tubes:
1. WHITE: Serum collected after blood clotted w/o centrifuging
2. 2 GREEN PRF PLUG: PRF plug collected after centrifuging and excision
3. BLUE PRF SN: Supernatant collected after PRF plug was made
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Appendix 3: Recruitment Flyer
Virginia Commonwealth University
Healthy Volunteers Wanted for a Research Study
Effects of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized Pro-resolving
Lipid Mediators in Autologous Platelet Concentrate Gels
The purpose of this research is to investigate the effects of two commonly available medications:
fish-oil supplement and baby aspirin, on certain lipid (fat) components of blood necessary for
wound healing. We will use sophisticated lab methods to accurately measure the blood levels of
these fats in healthy volunteers after taking EFA (fish-oil pill) and baby aspirin. The information
from this research will allow us to determine if taking either fish-oil or baby aspirin or both will
have beneficial effects on wound healing following surgery. The research is conducted under the
direction of Dr. Parthasarathy Madurantakam, Philips Institute of Oral Health Research, VCU
School of Dentistry.
The study will comprise of 60 participants and will involve two blood draws (60 ml each,
approximately 4 tbsp) following clinically approved protocols, 4 hours apart. Your participation
in this study will be limited to one half day and you will not be compensated for your
participation.
To be eligible, you should be a healthy adult (> 18 years of age and not having any known
medical condition), non-pregnant and weigh at least 110 lbs. In addition, you will not be eligible
to participate if you have:






History of smoking in the past 2 years
History of anti-coagulant, immunosuppresive or antibiotic therapy in the last 6 months
History of non-steroidal anti-inflammatory drug use (Advil, Tylenol or Aspirin) in the
past 1 month
History of fish-oil supplement (essential fatty acid) intake in the past month
Known allergy to fish-oil components or nuts

If you are interested and want to participate in this study or if you have any questions, please
contact
Kimberly Hollaway at klhollaway@vcu.edu or 804-828-4553
Dr. Madurantakam at madurantakap@vcu.edu or 804-828-9353
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Appendix 4: IRB approval and Consent form
This Box for IRB Office Use Only – Do Not Delete or Revise Template Rev Date: 6-19-14
RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM TITLE: Effects
of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized
Pro-resolving Lipid Mediators in Saliva and Autologous Platelet Concentrate Gels
VCU IRB PROTOCOL NUMBER: HM20002473 INVESTIGATOR: Dr. Parthasarathy
Madurantakam
You have been approached by the study doctor or the study staff because you have responded to
our request to volunteer in the above-mentioned study. If any information in this consent
document is not clear to you, please feel free to talk to the doctor or the staff involved in the
study. You may take home an unsigned copy of this consent form to think about or discuss with
family or friends before making your decision.
In this consent form, “you” always refers to the research participant.
PURPOSE OF THE STUDY
The purpose of this research is to investigate the effects of two commonly available medications:
fish-oil supplement and baby aspirin, on certain components in blood and saliva necessary for
wound healing. The information from this research will allow us to determine if taking either
fish-oil or baby aspirin or both has a beneficial effect on wound healing following surgical
procedures.
DESCRIPTION OF THE STUDY
It has been recently found that presence of adequate amounts of certain kind of fats is critical for
normal healing after surgery or trauma. Studying the blood levels of these fats was not possible
because precision instruments were not available. We will use the recent technological advances
to accurately measure the blood levels of these fats in healthy volunteers after taking EFA (fishoil pill) and baby aspirin. In addition, we will explore the potential of using saliva as an alternate
body fluid to blood to detect these fats.
Your participation will be limited to one day and we expect to enroll 60 study participants.
PROCEDURES
On the day of your scheduled appointment, a member of the research team will meet with you to
go over the details of the study and the informed consent process. You can use this opportunity
to ask any questions related to the study; seek more time to decide or may choose to not
participate in the study.
Once you sign the informed consent document, you will have the two procedures done: 1. We
will collect 4 ml of your saliva (that is normally secreted, unstimulated) into a
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plastic tube 2. A trained professional will draw 60 ml of your blood (4 tablespoons). This
amount is
well within the established safety limits. After the blood draw procedure, you will open a sealed
envelope to determine which group you would belong. The study has 4 groups based on the type
of medications the participants will take:
Group A will not take any pills
Group B will take one softgel of fish oil supplement (1400 mg, Sundown Naturals, NY) and a
second blood draw 4 hours later
Group C will take one tablet of Bayer low-dose (81 mg) aspirin and a second blood draw 4 hours
later
Group D will take fish-oil supplement first, low-dose aspirin 2 hours later and a second blood
draw 2 hours later
All your saliva and blood samples (baseline and at 4 hours) will be collected in a container that
contains your study ID number, age, sex and the timing of blood draw (time 0 or time 4hrs). No
personally identifiable information will be attached to the specimen and no one working in the
laboratory will know the source.
RISKS AND DISCOMFORTS
There are no known risks of saliva collection other than the possibility of you experiencing mild
discomfort due to dryness of the mouth.
Possible side effects associated with having blood drawn may involve:
Headache
Bruising and discoloration at the site
Pain
Dizziness
Prolonged bleeding
Currently, there is no evidence that aspirin and fish-oil interact to produce any complications.
BENEFITS TO YOU AND OTHERS This is not a treatment study, and you are not
expected to receive any direct benefits from your participation in the study. The information
from this research study may lead to better treatment in the future for people who undergo
surgery. PAYMENT FOR PARTICIPATION In order to compensate for your time and
procedures you are going through, we will pay you a total sum of $30 by cash. This money will
be paid at the end of second blood draw and saliva collection. No compensation will be provided
if you do not come back for the second appointment. In such circumstance, you will no longer be
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considered a study participant and your previously collected sample will not be used in the
analysis. ALTERNATIVE Your alternative is not to participate in the study.
CONFIDENTIALITY
Potentially identifiable information about you will consist of names, email addresses and phone
numbers. The investigator, research coordinator and the residents who work on this study will
have access to this information. At the end of the blood draw procedure, the blood will be
transferred into a separate container and labeled with a study ID number, your age, sex and the
time of sample collection (time 0 or time 4 hours). No personally identifiable information will be
attached to the specimen and hence no one working with the specimen in the laboratory will
know the source.
The research coordinator will store your identifiable information and link it to the study ID
number. This information will be kept separately in a locked research area and only the
coordinator and the PI will have access to this information. The personal identifiable information
and the study code will be destroyed at the end of the study while the consent forms will be kept
for a period of five years from the conclusion of the study in accordance to VCU policies.
Although results of this research may be presented at meetings or in publications, identifiable
personal information pertaining to participants will not be disclosed.
QUESTIONS
If you have any questions, complaints, or concerns about your participation in this research,
contact:
Dr. Parthasarathy Madurantakam
Assistant Professor Philips Institute, Room 4130 1101 East Leigh Street, Richmond, VA
23298 Telephone: (804) 828 9353 Email: madurantakap@vcu.edu
and/or
Ms. Kimberly Hollaway
Research Coordinator 521 North 11th Street, Richmond, Virginia 23298 Phone: (804) 8284553 Email: klhollaway@vcu.edu
The researcher/study staff named above is the best person(s) to call for questions about your
participation in this study.
If you have general questions about your rights as a participant in this or any other research, you
may contact:
Office of Research Virginia Commonwealth University 800 East Leigh Street, Suite 3000 P.O.
Box 980568 Richmond, VA 23298 Telephone: (804) 827-2157
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Contact this number for general questions, concerns, or complaints about research. You may also
call this number if you cannot reach the research team or if you wish to talk to someone else.
General information about participation in research studies can also be found at
http://www.research.vcu.edu/irb/volunteers.htm.
Do not sign this consent form unless you have had a chance to ask questions and have received
satisfactory answers to all of your questions.
CONSENT
I have been provided with an opportunity to read this consent form carefully. All of the questions
that I wish to raise concerning this study have been answered.
By signing this consent form, I have not waived any of the legal rights or benefits, to which I
otherwise would be entitled. My signature indicates that I freely consent to participate in this
research study. I will receive a copy of the consent form once I have agreed to participate.
Participant Name, printed
Participant Signature Date
Name of Person Conducting Informed Consent Date Discussion / Witness
Signature of Person Conducting Informed Consent Date Discussion / Witness
Principal Investigator Signature (if different from above) Date
Approved by the VCU IRB on 5/4/2015
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Appendix 5: Aspirin Regimen- Bayer® Low Dose Aspirin 81 mg insert

8
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Appendix 6: Brand of fish oil used in the study
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Appendix 7: Recruitment Flyer
Virginia Commonwealth University
Healthy Volunteers Wanted for a Research Study
Effects of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized Pro-resolving
Lipid Mediators in Autologous Platelet Concentrate Gels
The purpose of this research is to investigate the effects of two commonly available medications:
fish-oil supplement and baby aspirin, on certain lipid (fat) components of blood necessary for
wound healing. We will use sophisticated lab methods to accurately measure the blood levels of
these fats in healthy volunteers after taking EFA (fish-oil pill) and baby aspirin. The information
from this research will allow us to determine if taking either fish-oil or baby aspirin or both will
have beneficial effects on wound healing following surgery. The research is conducted under the
direction of Dr. Parthasarathy Madurantakam, Philips Institute of Oral Health Research, VCU
School of Dentistry.
The study will comprise of 60 participants and will involve two blood draws (60 ml each,
approximately 4 tbsp) following clinically approved protocols, 4 hours apart. Your participation
in this study will be limited to one half day and you will not be compensated for your
participation.
To be eligible, you should be a healthy adult (> 18 years of age and not having any known
medical condition), non-pregnant and weigh at least 110 lbs. In addition, you will not be eligible
to participate if you have:
● History of smoking in the past 2 years
● History of anti-coagulant, immunosuppresive or antibiotic therapy in the last 6 months
● History of non-steroidal anti-inflammatory drug use (Advil, Tylenol or Aspirin) in the
past 1 month
● History of fish-oil supplement (essential fatty acid) intake in the past month
● Known allergy to fish-oil components or nuts
If you are interested and want to participate in this study or if you have any questions, please
contact
Kimberly Hollaway at klhollaway@vcu.edu or 804-828-4553
Dr. Madurantakam at madurantakap@vcu.edu or 804-828-9353
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Dr. Danielle McCormack was born in Miami, Florida, and grew up in Port Charlotte, Florida.
She received a Bachelor of Science in Biology from Florida State University in 2009 before
attending Virginia Commonwealth University School of Dentistry, where she earned a Doctor of
Dental Surgery in 2014. She is a member of the American Dental Association, Virginia Dental
Association, and the American Academy of Periodontology. Dr. McCormack will graduate from
Virginia Commonwealth University with a Master of Science in Dentistry, and a Specialty
Certificate in Periodontics.
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